Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Apr 27, 2023 3:36pm
CEO Interview
More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it. AGN.c AGNPF is looking to
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Apr 27, 2023 12:51pm
Here we go again
Price down again, from 27 to 26 on one measly trade $130 from guess who? Integral
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 23, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Apr 26, 2023 4:37pm
Recent News
AGN.c AGNPF is continuing to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Apr 26, 2023 12:00pm
Trading Down
Price down again in early trading from 29 cents to 27.5. and who is trading? Integral and National Bank and PI Financial. And no big trades.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Apr 25, 2023 5:23pm
That’s Odd -Continued
At the end of the day just before close. Two trades thar drop the price from 30 cents to 29 cents, from the same two players - Intergral and National Bank. coincidence?
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Apr 25, 2023 10:57am
That’s Odd
At the opening, low bid was 29 cents and ask was 30 cents but the first trade, between Integral Financial and National Bank, was 500 at 28 cents. why would that be?
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Apr 24, 2023 3:56pm
Recent News
AGN.c AGNPF (up 7% today) announced last week they received a Notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 21, 2023 2:34pm
New Press Release - CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)
Toronto, Ontario--(Newsfile Corp. - le 21 avril/April 2023) - Algernon Pharmaceuticals Inc. Rights listed on March 28, 2023 will expire on April 27, 2023.Settlement Terms: All trades April 25 and 26 will be for cash next day settlement. Trades on April 27 will be for cash same day. The rights...
read article.
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Apr 21, 2023 11:37am
AGN receives US patent for CKD drug
Algernon Pharmaceuticals Inc.has received a Notice of Allowance from the United States Patent and Trademark Office for its lead drug NP-251 (Repirinast), a promising candidate for treating chronic
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 20, 2023 7:00am
New Press Release - Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is reminding its shareholders of the details of its previously announced...
read article.
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Apr 19, 2023 3:02pm
AGN Receives Notice of Allowance for its Lead CDK Drug
More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it. AGN.c AGNPF a Canadian
...more
(1167)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Apr 18, 2023 5:47pm
RE:News Update: $AGN CEO Chris Moreau - Patent NOA NP-251
Meanwhile, Chronic Cough anyone: T.BLU Post by PressReleaseon Apr 18, 2023 12:11pm New Press Release - GSK reaches agreement to acquire late-stage biopharmaceutical
...more
(35)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 18, 2023 12:21pm
News Update: $AGN CEO Chris Moreau - Patent NOA NP-251
News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Notice of Allowance from USPTO for NP-251 - https://youtu.be/Ot-kWEvA3m0 CEO Chris Moreau discusses Algernon's
...more
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Apr 17, 2023 6:54pm
AGN Patent Application News Summary
Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after announcing it received a Notice of Allowance from the US Patent and Trademark Office for its patent application for its
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 17, 2023 7:00am
New Press Release - Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >